Skip to main content

Dr. Sarah Wright, D.O.

Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)

At a glance

Years since graduation
10
In the NPI registry since
2016

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2016Medical school: New York College of Osteo Medicine of New York Institute of Technology
  • 2016Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology with Special Qualifications in Child Neurology Physician primary
    DC license DO210001335

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Child Neurology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Exondys-51 (eteplirsen)14

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 25 payments worth $23,805 in total to this clinician.

By company
Sarepta Therapeutics, Inc.$23,308
Genentech, Inc.$243
Genentech USA, Inc.$150
Biogen, Inc.$104
By type
Consulting Fee$19,955
Travel and Lodging$2,669
Food and Beverage$1,181

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 18, 2025Sarepta Therapeutics, Inc.
Dec 18, 2025
Consulting Fee
Elevidys · Genetic Disease
$11,815
May 15, 2025Sarepta Therapeutics, Inc.
May 15, 2025
Consulting Fee
Elevidys · Genetic Disease
$8,140
Dec 12, 2025Sarepta Therapeutics, Inc.
Dec 12, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind
$734
Dec 13, 2025Sarepta Therapeutics, Inc.
Dec 13, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind
$710
May 9, 2025Sarepta Therapeutics, Inc.
May 9, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Chicago, IL · in-kind
$434
Dec 12, 2025Sarepta Therapeutics, Inc.
Dec 12, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind
$261
Dec 13, 2025Sarepta Therapeutics, Inc.
Dec 13, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind
$255
May 9, 2025Sarepta Therapeutics, Inc.
May 9, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Chicago, IL · in-kind
$178
May 21, 2025Sarepta Therapeutics, Inc.
May 21, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Chicago, IL · in-kind
$70.00
May 21, 2025Sarepta Therapeutics, Inc.
May 21, 2025
Travel and Lodging
Elevidys · Genetic Disease · travel to Chicago, IL · in-kind
$26.32

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in District of Columbia →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $57,452 in research payments for these studies, mostly to the institutions running them.

  • An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG)…
    Alexion Pharmaceuticals, Inc.
  • Long term follow up study of patients with spinal muscular atrophy receiving risdiplam treatment
    Genentech, Inc.
  • Study name not reported
    Sarepta Therapeutics, Inc.
  • SRP-9001-401
    Sarepta Therapeutics, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Child Neurology clinicians in Washington

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 15, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1548624042. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.